|Bid||15.190 x 100|
|Ask||22.800 x 100|
|Day's Range||20.570 - 21.550|
|52 Week Range||11.410 - 24.880|
|PE Ratio (TTM)||-15.65|
|Earnings Date||Aug 1, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||24.88|
SAN FRANCISCO, May 22, 2017 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that Takeda Pharmaceutical Company Limited (TSE: 4502) and Nektar have entered into a research collaboration to explore the combination of Nektar's lead immuno-oncology candidate, the CD122-biased agonist NKTR-214, with five oncology compounds from Takeda's cancer portfolio. The two companies will explore the anti-cancer activity of NKTR-214 with five different targeted mechanisms in preclinical tumor models of lymphoma, melanoma and colorectal cancer. "We look forward to collaborating with Takeda to explore a range of combination therapy approaches in models of both liquid and solid tumors," said Jonathan Zalevsky, PhD, Senior Vice President of Biology and Preclinical Development.
Incyte stock enjoyed a fifth consecutive day of gains Friday after its immuno-oncology drug proved robust in combination trials with Merck and Bristol.
Categories: ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Nektar Therapeutics. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)